Shine Medical Technologies has closed a new financing round worth $150 million that will support its ongoing medical isotope commercialization efforts, the company announced Monday.

Venture capital firm Koch Disruptive Technologies (KDT) led this series C-5 round with Fidelity Management & Research Company, Scotland-based investment firm Baillie Gifford, and other new and current investors also contributing.

Greg Piefer, chairman and CEO of Janesville, Wisconsin-based Shine said KDT will be an “incredible” partner as the nuclear medicine tech company seeks to become the world’s largest capacity medical isotope plant.

“Shine’s mission is to usher in a new era of nuclear fusion technology and Koch, which is among the biggest players in energy, is a great long-term, strategic match for us as we pursue our ultimate goal: fusion-based clean energy,” Piefer said in a statement. “We are grateful for their confidence and investment in Shine.”